SMARCA4 and sarcoma: Several case studies of checkpoint inhibitor therapy in thoracic SMARCA4-deficient sarcomas have emphasised that some patients display exceptional and durable responses to anti-PD-1 blockade, although responses were observed in both PD-L1 positive and negative SMARCA4 tumours [64,65,66].